search
Back to results

Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism

Primary Purpose

Primary Aldosteronism, Endocrine Hypertension

Status
Recruiting
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Cinnarizine
NIFEdipine ER
Sponsored by
Queen Mary University of London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Primary Aldosteronism focused on measuring Primary aldosteronism, Calcium channel blocker, Aldosterone

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Confirmed PA, as demonstrated by a positive screening test and internationally endorsed confirmatory test (saline suppression test, captopril challenge test) Adults > 18 years of age Able and willing to give informed consent Exclusion Criteria: Uncontrolled hypertension requiring use of MRA Unwilling or unable to give consent Below age 18 or above age 90 years Allergy to cinnarizine or nifedipine or their excipients Existing use of cinnarizine or nifedipine for an alternative indication Breastfeeding or pregnant women Diagnosis of Parkinson's disease Severe hepatic or renal insufficiency Concurrent use of sedating central nervous system (CNS) depressants or rifampicin Porphyria Cardiogenic shock, clinically significant aortic stenosis, unstable angina, within one month of a myocardial infarction Previous gastro-intestinal or oesophageal obstruction or ileostomy

Sites / Locations

  • St Bartholomew's HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Cinnarizine and nifedipine

Arm Description

Drug 1 for 2 weeks, 2 weeks of washout, then Drug 2 for 2 weeks Drug 1 and 2, in no specified order, Cinnarizine 30 mg oral TDS and Nifedipine 60 mg oral daily

Outcomes

Primary Outcome Measures

Aldosterone change
Evaluate whether the effect of calcium channel blockade on plasma aldosterone levels is due primarily to Cav1.3 blockade in individuals with PA and clinical features suggesting an increased likelihood of a CACNA1D mutation.

Secondary Outcome Measures

Blood pressure change
Evaluate whether the use of a proposed Cav1.3 inhibitor affects blood pressure in individuals with PA, evaluating both systolic blood pressure and diastolic blood pressure.

Full Information

First Posted
December 22, 2022
Last Updated
May 22, 2023
Sponsor
Queen Mary University of London
search

1. Study Identification

Unique Protocol Identification Number
NCT05686993
Brief Title
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism
Official Title
Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism - a Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 5, 2023 (Actual)
Primary Completion Date
October 6, 2023 (Anticipated)
Study Completion Date
December 6, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Queen Mary University of London

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this pilot, open-label prospective study is to evaluate if the effect of calcium channel blockade on plasma aldosterone levels in people with primary aldosteronism (PA) is due primarily to Cav1.3 blockade. This will be tested by treating participants who have PA with both cinnarizine (Cav1.3 blocker) and nifedipine (Cav1.2 blocker) and evaluating effect on aldosterone levels and blood pressure over a two week course of treatment.
Detailed Description
Medical treatment for Primary Aldosteronism (PA) is currently limited to mineralocorticoid receptor antagonists (MRA), the most widely available of which is spironolactone. This can cause numerous adverse effects, especially in men, due to interference with androgen and progesterone signalling. Hence, alternative drug targets are needed, one potential of which is Cav1.3. The CACNA1D mutation in PA affects the calcium channel Cav1.3. Cav1.3 inhibition may offer targeted treatment for patients with mutations in CACNA1D. Cav1.3 has been a candidate for novel inhibitors of aldosterone production,4 for which the case is enhanced if CACNA1D-mutations underlie the above-described phenotype of PA (asymmetric disease leading to failure to achieve cure with adrenalectomy). The calcium-channel blocker, cinnarizine, typically used for vertigo and nausea, has been identified to fit the recently described crystal structure of Cav1.3. This raises the possibility of using this drug to assess the effect of Cav1.3 inhibition in PA. This may lead to further studies involving randomisation and placebo to determine if Cav1.3 inhibition is an important method by which aldosterone levels can be lowered in people with PA. This study seeks to explore whether the effect of calcium channel blockade on aldosterone levels in people with PA is due to Cav1.3 blockade, by comparing cinnarizine (proposed Cav1.3 inhibitor) to a conventional calcium channel blocker nifedipine (Cav1.2 inhibitor). Cinnarizine is not a likely prospect for long-term treatment of PA, because of its potential additional actions as well as Cav1.3 blockade, but using it in this setting, for a short period of time, allows exploration of a property of this existing drug (Cav1.3 inhibition). Outcomes could form the basis of further exploration of this mechanism for future PA treatments.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Primary Aldosteronism, Endocrine Hypertension
Keywords
Primary aldosteronism, Calcium channel blocker, Aldosterone

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Treatment with 2 study drugs with 2 weeks of drug washout in between Study drug treatments are: cinnarizine for 2 weeks, nifedipine for 2 weeks Order randomly determined by computer program, with results released by an independent clinician as patients are recruited
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cinnarizine and nifedipine
Arm Type
Experimental
Arm Description
Drug 1 for 2 weeks, 2 weeks of washout, then Drug 2 for 2 weeks Drug 1 and 2, in no specified order, Cinnarizine 30 mg oral TDS and Nifedipine 60 mg oral daily
Intervention Type
Drug
Intervention Name(s)
Cinnarizine
Other Intervention Name(s)
Stugeron, Stunarone, Cinarin
Intervention Description
Cinnarizine oral 30mg TDS
Intervention Type
Drug
Intervention Name(s)
NIFEdipine ER
Other Intervention Name(s)
Adalat, Adipine, Coracten, Fortipine, Nifedipress
Intervention Description
Nifedipine oral 60mg daily extended release
Primary Outcome Measure Information:
Title
Aldosterone change
Description
Evaluate whether the effect of calcium channel blockade on plasma aldosterone levels is due primarily to Cav1.3 blockade in individuals with PA and clinical features suggesting an increased likelihood of a CACNA1D mutation.
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Blood pressure change
Description
Evaluate whether the use of a proposed Cav1.3 inhibitor affects blood pressure in individuals with PA, evaluating both systolic blood pressure and diastolic blood pressure.
Time Frame
6 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Confirmed PA, as demonstrated by a positive screening test and internationally endorsed confirmatory test (saline suppression test, captopril challenge test) Adults > 18 years of age Able and willing to give informed consent Exclusion Criteria: Uncontrolled hypertension requiring use of MRA Unwilling or unable to give consent Below age 18 or above age 90 years Allergy to cinnarizine or nifedipine or their excipients Existing use of cinnarizine or nifedipine for an alternative indication Breastfeeding or pregnant women Diagnosis of Parkinson's disease Severe hepatic or renal insufficiency Concurrent use of sedating central nervous system (CNS) depressants or rifampicin Porphyria Cardiogenic shock, clinically significant aortic stenosis, unstable angina, within one month of a myocardial infarction Previous gastro-intestinal or oesophageal obstruction or ileostomy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elisabeth Ng, MBBS FRACP
Phone
+61423054098
Email
elisabethhng@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Morris Brown, MD FRCP
Phone
+44(0) 20 7882 3901
Email
morris.brown@qmul.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Morris Brown, MD FRCP
Organizational Affiliation
Queen Mary University of London
Official's Role
Principal Investigator
Facility Information:
Facility Name
St Bartholomew's Hospital
City
London
ZIP/Postal Code
EC1A 7BE
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elisabeth Ng, MBBS FRACP
Email
elisabeth.ng@nhs.net

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Effect of a Proposed Cav1.3 Inhibitor in Primary Aldosteronism

We'll reach out to this number within 24 hrs